Claims:

1. Use of vaccinal dengue viruses of four serotypes for the manufacture of a medicament for use in a method of inducing neutralizing antibodies against four serotypes of dengue fever virus, mumps virus, measles virus and rubella virus in a mammal, wherein said method comprises the administration of the vaccinal dengue viruses of four serotypes and the co-administration of an MMR vaccinal composition to said mammal.

2. The use of claim 1 wherein the administration of vaccinal dengue viruses of four serotypes is achieved by the administration of a tetravalent vaccinal virus composition.

3. The use of claim 1 wherein the administration of vaccinal dengue viruses of four serotypes is achieved by the co-administration of two bivalent vaccinal dengue virus compositions.

4. The use of claim 1 wherein the administration of vaccinal dengue viruses of four serotypes is achieved by the co-administration of four monovalent vaccinal dengue virus compositions.

5. The use of claim 2 wherein the tetravalent vaccinal virus composition comprises Chimerivax™ DEN-1, 2, 3 and 4.

6. The use of claim 2 wherein the quantity of vaccinal viruses of dengue fever of serotypes 1, 2, 3 and 4 lies within a range from 10^3 to 10^6 $CCID_{50}$.

7. The use of any of claim 1-6 wherein the MMR vaccinal composition is a trivalent MMR vaccinal composition.

8. An immunization kit against dengue fever, mumps, measles and rubella comprising a box containing at least (a) a first container holding a trivalent MMR vaccine and (b) a second container holding a tetravalent vaccine comprising vaccinal viruses for four serotypes of dengue fever, wherein said MMR vaccine and said vaccine comprising vaccinal viruses for four serotype of dengue fever are for use in a method of inducing neutralizing antibodies against the four serotypes of dengue fever virus, mumps virus, measles virus and rubella virus in a mammal, wherein said method comprosies the administration of said vaccine comprising vaccinal viruses for the four serotypes of dengue fever and the co-administration of said MMR vaccine.

9. The kit of claim 8 further comprising a third container holding a solvent for reconstitution.

10. The kit of claims 8 or 9 wherein the container is a pre-filled syringe.

~~11. The kit of any one of claims 8 to 10, wherein said MMR vaccine and said vaccine comprising vaccinal viruses for four serotype of dengue fever are for use in a method of inducing neutralizing antibodies against the four serotypes of dengue fever virus, mumps virus, measles virus and rubella virus in a mammal, wherein said method comprosies the administration of said vaccine comprising vaccinal viruses for the four serotypes of dengue fever and the co-administration of said MMR vaccine.~~

~~12~~11. The use of tetravalent dengue and trivalent MMR vaccinal viruses for the manufacture of a vaccine for immunization against dengue, mumps, measles and rubella virus in which the

tetravalent vaccine comprises vaccinal viruses for four serotypes of dengue and in which the tetravalent dengue vaccine is used within 3 days of use of the MMR vaccinal viruses.

~~13~~12. Use of an MMR vaccinal composition for the manufacture of a medicament for use in a method of inducing neutralizing antibodies against four serotypes of dengue fever virus, mumps virus, measles virus and rubella virus in a mammal, wherein said method comprises the administration of the MMR vaccinal composition and the co-administration of vaccinal dengue viruses of four serotypes to said mammal.

~~14~~13. The use of claim ~~13~~12, wherein the administration of the MMR vaccinal composition is achieved by the concomitant administration of a monovalent measles, a monovalent mumps and a monovalent rubella vaccinal composition.

~~15~~14. The use of claim ~~13~~12, wherein the administration of the MMR vaccinal composition is achieved by the administration of a trivalent composition comprising vaccinal measles, mumps and rubella viruses.